Immune Checkpoint Inhibitors in Melanoma and HIV Infection
Antonio Marra1, Giosuè Scognamiglio2, Ilaria Peluso3, Gerardo Botti2, Celeste Fusciello4, Amelia Filippelli5, Paolo A. Ascierto6, Stefano Pepe4, Francesco Sabbatino4, *
Identifiers and Pagination:Year: 2017
First Page: 91
Last Page: 100
Publisher ID: TOAIDJ-11-91
Article History:Received Date: 29/05/2017
Revision Received Date: 10/10/2017
Acceptance Date: 13/10/2017
Electronic publication date: 14/11/2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Immunotherapy with immune checkpoint inhibitors increases the overall survival of patients with metastatic melanoma regardless of their oncogene addicted mutations. However, no data is available from clinical trials of effective therapies in subgroups of melanoma patients that carry chronic infective diseases such as HIV. Evidences suggest a key role of the immune checkpoint molecules as a mechanism of immune escape not only from melanoma but also from HIV host immune response.
In this article, firstly, we will describe the role of the immune checkpoint molecules in HIV chronic infection. Secondly, we will summarize the most relevant clinical evidences utilizing immune checkpoint inhibitors for the treatment of melanoma patients. Lastly, we will discuss the potential implications as well as the potential applications of immune checkpoint molecule-based immunotherapy in patients with melanoma and HIV infection.